PortfoliosLab logo
Akari Therapeutics, Plc (AKTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00972G1085

CUSIP

00972G108

IPO Date

Sep 21, 2015

Highlights

Market Cap

$42.16M

EBITDA (TTM)

-$14.08M

Year Range

$0.85 - $4.40

Target Price

$80.00

Short %

0.32%

Short Ratio

2.32

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akari Therapeutics, Plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%NovemberDecember2025FebruaryMarchApril
-99.77%
180.90%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Returns By Period

Akari Therapeutics, Plc had a return of 17.21% year-to-date (YTD) and 20.68% in the last 12 months.


AKTX

YTD

17.21%

1M

10.00%

6M

-39.52%

1Y

20.68%

5Y*

-47.62%

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.06%

1M

-2.95%

6M

-4.87%

1Y

8.34%

5Y*

13.98%

10Y*

10.15%

*Annualized

Monthly Returns

The table below presents the monthly returns of AKTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-10.66%-20.18%42.53%15.32%17.21%
2024-16.03%-10.31%-20.64%-17.43%11.30%57.53%43.33%-1.03%-22.98%-18.64%-49.58%0.83%-60.90%
2023-0.66%-26.09%-47.33%-0.33%-2.32%-3.90%46.82%-36.90%25.40%-13.67%-13.49%5.76%-66.80%
2022-8.67%-1.46%-11.11%-0.83%-1.68%-14.54%14.01%4.39%-47.06%-26.06%18.63%-14.97%-68.67%
202136.76%32.41%-21.19%-21.97%-12.86%-3.62%-6.36%13.58%-11.41%1.84%-1.81%-7.98%-18.92%
20202.86%2.22%-21.20%32.41%6.25%6.86%-7.80%-14.43%1.16%-13.79%6.67%15.62%5.71%
201928.01%-9.94%97.79%-0.00%-46.93%6.32%-6.93%10.64%-17.79%11.11%8.42%-15.05%11.46%
2018-33.95%-31.82%-6.67%4.95%-3.66%5.98%-1.54%-2.08%36.17%-29.69%-0.56%-12.29%-63.74%
201713.64%-18.62%70.05%35.41%-59.11%-24.80%0.87%-23.66%72.96%-30.13%13.29%-10.91%-38.49%
2016-4.57%-30.19%44.93%22.86%-12.21%-10.66%-31.06%1.72%-10.04%11.05%-24.34%-1.54%-51.45%
2015-23.83%-20.40%1.57%-25.25%-53.97%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AKTX is 63, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AKTX is 6363
Overall Rank
The Sharpe Ratio Rank of AKTX is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of AKTX is 7070
Sortino Ratio Rank
The Omega Ratio Rank of AKTX is 6868
Omega Ratio Rank
The Calmar Ratio Rank of AKTX is 6262
Calmar Ratio Rank
The Martin Ratio Rank of AKTX is 5757
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for AKTX, currently valued at 0.15, compared to the broader market-2.00-1.000.001.002.003.00
AKTX: 0.15
^GSPC: 0.46
The chart of Sortino ratio for AKTX, currently valued at 1.11, compared to the broader market-6.00-4.00-2.000.002.004.00
AKTX: 1.11
^GSPC: 0.77
The chart of Omega ratio for AKTX, currently valued at 1.14, compared to the broader market0.501.001.502.00
AKTX: 1.14
^GSPC: 1.11
The chart of Calmar ratio for AKTX, currently valued at 0.18, compared to the broader market0.001.002.003.004.005.00
AKTX: 0.18
^GSPC: 0.47
The chart of Martin ratio for AKTX, currently valued at 0.35, compared to the broader market-5.000.005.0010.0015.0020.00
AKTX: 0.35
^GSPC: 1.94

The current Akari Therapeutics, Plc Sharpe ratio is 0.15. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Akari Therapeutics, Plc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.15
0.46
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Dividends

Dividend History


Akari Therapeutics, Plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-99.77%
-10.07%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akari Therapeutics, Plc was 99.86%, occurring on Feb 28, 2025. The portfolio has not yet recovered.

The current Akari Therapeutics, Plc drawdown is 99.77%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.86%Sep 22, 20152327Feb 28, 2025

Volatility

Volatility Chart

The current Akari Therapeutics, Plc volatility is 26.99%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%NovemberDecember2025FebruaryMarchApril
26.99%
14.23%
AKTX (Akari Therapeutics, Plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akari Therapeutics, Plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Akari Therapeutics, Plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
AKTX: 0.0
The chart displays the Price-to-Earnings (P/E) ratio for AKTX, comparing it with other companies in the Biotechnology industry. Currently, AKTX has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
2.04.06.08.010.0
AKTX: 0.0
The chart shows the Price/Earnings to Growth (PEG) ratio for AKTX compared to other companies in the Biotechnology industry. AKTX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
20.040.060.080.0100.0
AKTX: 0.0
This chart shows the Price-to-Sales (P/S) ratio for AKTX relative to other companies in the Biotechnology industry. Currently, AKTX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
2.04.06.08.010.0
AKTX: 1.9
The chart illustrates the Price-to-Book (P/B) ratio for AKTX in comparison with other companies in the Biotechnology industry. Currently, AKTX has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items